Board Change • Jul 01
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 5 highly experienced directors. Independent Director Jou-Kou Wang was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Duyuru • Mar 11
Medigen Biotechnology Corp., Annual General Meeting, May 26, 2026 Medigen Biotechnology Corp., Annual General Meeting, May 26, 2026. Location: 2 floor building. a no,19-10, san ch`ung rd., nangang district, taipei city Taiwan Reported Earnings • Nov 13
Third quarter 2025 earnings released: NT$0.41 loss per share (vs NT$0.19 loss in 3Q 2024) Third quarter 2025 results: NT$0.41 loss per share (further deteriorated from NT$0.19 loss in 3Q 2024). Revenue: NT$395.7m (down 9.4% from 3Q 2024). Net loss: NT$56.4m (loss widened 110% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 17
Second quarter 2025 earnings released: NT$0.27 loss per share (vs NT$0.086 profit in 2Q 2024) Second quarter 2025 results: NT$0.27 loss per share (down from NT$0.086 profit in 2Q 2024). Revenue: NT$360.8m (up 1.9% from 2Q 2024). Net loss: NT$38.0m (down 418% from profit in 2Q 2024). Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Reported Earnings • May 15
First quarter 2025 earnings released: EPS: NT$0.74 (vs NT$0.54 loss in 1Q 2024) First quarter 2025 results: EPS: NT$0.74 (up from NT$0.54 loss in 1Q 2024). Revenue: NT$499.4m (up 99% from 1Q 2024). Net income: NT$102.5m (up NT$178.2m from 1Q 2024). Profit margin: 21% (up from net loss in 1Q 2024). Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. Duyuru • May 03
Medigen Biotechnology Corp. to Report Q1, 2025 Results on May 12, 2025 Medigen Biotechnology Corp. announced that they will report Q1, 2025 results on May 12, 2025 Reported Earnings • Mar 19
Full year 2024 earnings released: NT$1.47 loss per share (vs NT$4.03 loss in FY 2023) Full year 2024 results: NT$1.47 loss per share (improved from NT$4.03 loss in FY 2023). Revenue: NT$1.37b (up 19% from FY 2023). Net loss: NT$204.7m (loss narrowed 64% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings. Duyuru • Mar 11
Medigen Biotechnology Corp., Annual General Meeting, Jun 05, 2025 Medigen Biotechnology Corp., Annual General Meeting, Jun 05, 2025. Location: 2 floor building. a no,19-10, san ch`ung rd., nangang district, taipei city Taiwan Duyuru • Mar 04
Medigen Biotechnology Corporation Announces Resignation of Chieh-Liang Lin as Chief Scientific Officer Medigen Biotechnology Corporation announced the resignation of Mr. Chieh-Liang Lin from his position as Chief Scientific Officer, effective March 3, 2025. The resignation is due to business adjustments, and Mr. Lin has been transferred to a subsidiary where he will serve as Chief Operating Officer and Chief Technology Officer. Duyuru • Feb 28
Medigen Biotechnology Corp. to Report Q4, 2024 Results on Mar 10, 2025 Medigen Biotechnology Corp. announced that they will report Q4, 2024 results on Mar 10, 2025 Reported Earnings • Nov 19
Third quarter 2024 earnings released: NT$0.19 loss per share (vs NT$0.34 loss in 3Q 2023) Third quarter 2024 results: NT$0.19 loss per share (improved from NT$0.34 loss in 3Q 2023). Revenue: NT$436.6m (up 4.7% from 3Q 2023). Net loss: NT$26.9m (loss narrowed 43% from 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings. Duyuru • Oct 29
Medigen Biotechnology Corp. to Report Q3, 2024 Results on Nov 05, 2024 Medigen Biotechnology Corp. announced that they will report Q3, 2024 results on Nov 05, 2024 Reported Earnings • Aug 15
Second quarter 2024 earnings released: EPS: NT$0.08 (vs NT$0.70 loss in 2Q 2023) Second quarter 2024 results: EPS: NT$0.08 (up from NT$0.70 loss in 2Q 2023). Revenue: NT$354.1m (up 72% from 2Q 2023). Net income: NT$11.9m (up NT$109.3m from 2Q 2023). Profit margin: 3.4% (up from net loss in 2Q 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings. Duyuru • Aug 10
Medigen Biotechnology Corp. Announces Change of Accounting Officer, Effective September 1, 2024 Medigen Biotechnology Corp. announced change of accounting officer. Name, title, and resume of the previous position holder: I-Ju Chen, Medigen accounting officer. Name, title, and resume of the new position holder: Feng-Hua Chen,Medigen financial officer. Effective date: September 1, 2024. Duyuru • Aug 06
Medigen Biotechnology Corp. to Report Q2, 2024 Results on Aug 09, 2024 Medigen Biotechnology Corp. announced that they will report Q2, 2024 results on Aug 09, 2024 Duyuru • Jun 08
Medigen Biotechnology Corp. Announces Taiwan Mohw Approves A New Version of the Collaborative Autologous Natural Killer Cell Therapy Project by the Company and Wanfang Hospital Medigen Biotechnology Corp. announced Taiwan Mohw Approves A New Version of the Collaborative Autologous Natural Killer Cell Therapy Project by the Company and Wanfang Hospital. Medigen, in collaboration with Taipei Municipal Wanfang Hospital managed by Taipei Medical University (referred to as Wanfang Hospital), has applied to the Ministry of Health and Welfare (MOHW) on January 22, 2024, for a new version of the Autologous Natural Killer (Magicell-NK) cell therapy project for treating stage IV solid tumors in accordance with the regulations of the ”Regulations Governing the Application of Specific Medical Examination Technique and Medical Device”. On June 6, 2024, Medigen received the approval letter from the Ministry of Health and Welfare, confirming that Medigen's Cell Processing Unit is compliant with Good Tissue Practice (GTP). Details on the approved items in the abovementioned Wanfang Hospital cell therapy project: (1)Type of Cell Therapy: Autologous natural killer cells (NK cells) - Magicell-NK. (2) Indications: Stage IV solid tumors, including Brain cancer, breast cancer, lung cancer, esophageal cancer, stomach cancer, liver cancer, bile duct cancer, pancreatic cancer, prostate cancer, colorectal cancer. (3) Cell Processing Unit: Medigen’s cell processing unit (4)Validity Period: From June 4, 2024, to February 2, 2026. Reported Earnings • May 19
First quarter 2024 earnings released: NT$0.54 loss per share (vs NT$0.68 loss in 1Q 2023) First quarter 2024 results: NT$0.54 loss per share (improved from NT$0.68 loss in 1Q 2023). Revenue: NT$251.3m (up 53% from 1Q 2023). Net loss: NT$75.7m (loss narrowed 20% from 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 42% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings. Duyuru • May 03
Medigen Biotechnology Corp. to Report Q1, 2024 Results on May 10, 2024 Medigen Biotechnology Corp. announced that they will report Q1, 2024 results on May 10, 2024 Reported Earnings • Mar 17
Full year 2023 earnings released: NT$4.03 loss per share (vs NT$4.86 loss in FY 2022) Full year 2023 results: NT$4.03 loss per share (improved from NT$4.86 loss in FY 2022). Revenue: NT$1.16b (up 9.6% from FY 2022). Net loss: NT$561.3m (loss narrowed 17% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings. Duyuru • Mar 13
Medigen Biotechnology Corp. Announces Appointment of Chieh-Liang Lin as Chief Scientific Officer Medigen Biotechnology Corp. announced the appointment of Mr. Chieh-Liang Lin, Senior Associate Vice President of Cell Therapy Department of the company, as Chief Scientific Officer. Approved by the Board of Directors on March 11, 2024. Duyuru • Mar 12
Medigen Biotechnology Corp., Annual General Meeting, May 28, 2024 Medigen Biotechnology Corp., Annual General Meeting, May 28, 2024. Location: 2nd Floor, Building A, No. 19-10,Sanchong Road, Nangang District International Convention Center Taipei City Taiwan Agenda: To consider 2023 business report; to consider audit committee's review of the 2023 annual final accounting books and statements; to consider report on the revision of some provisions of the company's rules of procedure for board meetings; to consider 2023 business report and financial statements; to consider loss of appropriation proposal of the 2023; to consider re-election of all directors of the company; to consider lifting the restrictions on non-competition for newly elected directors and their representatives; and to consider other issues. Duyuru • Mar 01
Medigen Biotechnology Corp. Applies to the Taiwan Food and Drug Administration for Phase I/Ii Clinical Trial Ofallogeneic Natural Killer Cells (Magicell-NK) Medigen Biotechnology Corp. has applied to the Taiwan Food and Drug Administration (TFDA) for Phase I/II clinical trial of allogeneic natural killer cells (Magicell-NK). New drug name or code: Allogeneic natural killer cells (Magicell-NK). Indication: The application of Phase I/II clinical trial of allogeneic natural killer (NK) cells submitted to the Taiwan Food and Drug Administration (TFDA) involves the use of company's proprietary and independently developed allogeneic natural killer cell expansion technology, Magicell-NK. This technology utilizes blood from donors, which is cultured, activated, and expanded ex vivo to prepare natural killer cell products. These products are then administered back into the patients and will be used as adjuvant therapy post-surgery, in combination with chemotherapy, for pancreatic ductal adenocarcitnoma (PDA) or bile duct cancer patients, aiming to prevent recurrence and increase survival time. Planned development stages: Phase I/II clinical trial. Current development stage: Application submission/approval/disapproval/each of clinical trials (include interim analysis): Submitted an application for Phase I/II clinical trial to TFDA. Accumulated investment expenditure incurred: Due to considerations of commercial strategy, disclosure is temporarily withheld. Upcoming development plan: Phase I/II clinical trial will commence upon obtaining approval from the TFDA and the Institutional Review Board (IRB). Estimated Completion Time: Expected to be completed in 2029, the actual schedule will be adjusted according to the progress of execution. Expected Obligations: company will bear the expenses related to clinical trials and related registration fees. Duyuru • Jan 12
the Ministry of Health and Welfare Approves the Collaborative Autologous Gamma-Deltat Cell Therapy Project by Medigen Biotechnology Corp.And Taichung Tzu Chi Hospital Medigen Biotechnology Corporation in collaboration with Taichung Tzu Chi Hospital applied for the Autologous Gamma-Delta T (Magicell-GDT) cell therapy project. On January 11, 2024, Medigen received the approval letter from the competent authority, the Ministry of Health and Welfare, confirming that Medigen's Cell Processing Unit is compliant with Good Tissue Practice (GTP). In accordance with the regulations of the Regulations Governing the Application of Specific Medical examination technique and Medical Device, the Magicell-GDT cells produced at Medigen's Cell Processing Unit can be used for treating stage IV solid tumors at Taichung Tzu Chi hospital. Countermeasures: The announcement was released in accordance with the approval letter of the Ministry of Health and Welfare .Any other matters that need to be specified: (1) Details on the approved items in the abovementioned Taichung Tzu Chi Hospital cell therapy project: A.Type of cell therapy: Autologous Gamma-Delta T cell (Magicell-GDT) B.Indication: Stage IV solid tumor; Lung cancer, breast cancer, kidney cancer, prostate cancer, pancreatic cancer, colorectal cancer C.Cell processing unit: Medigen’s cell processing unit D. Approval period: From January 9, 2024 to February 2, 2026 (2) The manufacturing technology of this approved Gamma-Delta T cell is exclusively licensed from the Japanese listed company MEDINET Co. Ltd. (please see Medigen’s announcement released on 7th October, 2019). New Risk • Oct 20
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 5.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 2.3% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (5.9% average weekly change). New Risk • Aug 13
New major risk - Revenue and earnings growth Earnings have declined by 2.3% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company. Reported Earnings • Aug 12
Second quarter 2023 earnings released: NT$0.70 loss per share (vs NT$0.88 loss in 2Q 2022) Second quarter 2023 results: NT$0.70 loss per share (improved from NT$0.88 loss in 2Q 2022). Revenue: NT$205.6m (up 7.3% from 2Q 2022). Net loss: NT$97.3m (loss narrowed 21% from 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 21% per year whereas the company’s share price has fallen by 23% per year. Reported Earnings • Nov 19
Third quarter 2022 earnings released: NT$0.84 loss per share (vs NT$0.46 profit in 3Q 2021) Third quarter 2022 results: NT$0.84 loss per share (down from NT$0.46 profit in 3Q 2021). Revenue: NT$176.0m (down 87% from 3Q 2021). Net loss: NT$116.2m (down 283% from profit in 3Q 2021). Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings. Board Change • Nov 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. 1 independent director (8 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Aug 15
Second quarter 2022 earnings released: NT$0.88 loss per share (vs NT$0.93 loss in 2Q 2021) Second quarter 2022 results: NT$0.88 loss per share (up from NT$0.93 loss in 2Q 2021). Revenue: NT$191.6m (up 9.5% from 2Q 2021). Net loss: NT$122.8m (loss narrowed 5.0% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings. Reported Earnings • May 19
First quarter 2022 earnings released: NT$0.59 loss per share (vs NT$0.46 loss in 1Q 2021) First quarter 2022 results: NT$0.59 loss per share (down from NT$0.46 loss in 1Q 2021). Revenue: NT$484.7m (up 161% from 1Q 2021). Net loss: NT$81.7m (loss widened 28% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. 1 independent director (8 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Apr 01
Full year 2021 earnings released: NT$0.38 loss per share (vs NT$2.43 loss in FY 2020) Full year 2021 results: NT$0.38 loss per share (up from NT$2.43 loss in FY 2020). Revenue: NT$3.92b (up NT$3.31b from FY 2020). Net loss: NT$52.6m (loss narrowed 84% from FY 2020). Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Reported Earnings • Nov 16
Third quarter 2021 earnings released: EPS NT$0.46 (vs NT$0.80 loss in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: NT$1.39b (up NT$1.23b from 3Q 2020). Net income: NT$63.6m (up NT$174.2m from 3Q 2020). Profit margin: 4.6% (up from net loss in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 9% per year whereas the company’s share price has increased by 8% per year. Reported Earnings • Aug 15
Second quarter 2021 earnings released: NT$0.93 loss per share (vs NT$0.65 loss in 2Q 2020) The company reported a soft second quarter result with increased losses and weaker control over costs, although revenues improved. Second quarter 2021 results: Revenue: NT$174.9m (up 25% from 2Q 2020). Net loss: NT$129.3m (loss widened 43% from 2Q 2020). Over the last 3 years on average, earnings per share has remained flat but the company’s share price has increased by 35% per year, which means it is well ahead of earnings. Reported Earnings • May 15
First quarter 2021 earnings released: NT$0.46 loss per share (vs NT$0.51 loss in 1Q 2020) The company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2021 results: Revenue: NT$185.7m (up 42% from 1Q 2020). Net loss: NT$64.1m (loss narrowed 9.1% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 24% per year, which means it is well ahead of earnings. Reported Earnings • Mar 31
Full year 2020 earnings released: NT$2.43 loss per share (vs NT$2.84 loss in FY 2019) The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: NT$615.5m (up 11% from FY 2019). Net loss: NT$337.9m (loss narrowed 14% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 21% per year, which means it is well ahead of earnings. Is New 90 Day High Low • Feb 20
New 90-day high: NT$66.60 The company is up 9.0% from its price of NT$61.00 on 20 November 2020. The Taiwanese market is up 18% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is up 1.0% over the same period. Is New 90 Day High Low • Jan 27
New 90-day low: NT$49.30 The company is down 13% from its price of NT$56.70 on 30 October 2020. The Taiwanese market is up 21% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period. Is New 90 Day High Low • Jan 11
New 90-day low: NT$55.40 The company is down 12% from its price of NT$63.10 on 14 October 2020. The Taiwanese market is up 19% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period. Reported Earnings • Nov 14
Third quarter 2020 earnings released: NT$0.79 loss per share The company reported a solid third quarter result with improved revenues and control over expenses, though losses increased. Third quarter 2020 results: Revenue: NT$154.1m (up 40% from 3Q 2019). Net loss: NT$110.6m (loss widened 28% from 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 16% per year, which means it is well ahead of earnings. Is New 90 Day High Low • Oct 29
New 90-day low: NT$57.50 The company is down 26% from its price of NT$77.50 on 31 July 2020. The Taiwanese market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 9.0% over the same period. Is New 90 Day High Low • Oct 13
New 90-day low: NT$63.10 The company is down 27% from its price of NT$86.70 on 15 July 2020. The Taiwanese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 16% over the same period. Is New 90 Day High Low • Sep 25
New 90-day low: NT$65.20 The company is down 18% from its price of NT$79.50 on 24 June 2020. The Taiwanese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period. Duyuru • Sep 23
TBG Biotechnology Corp. Enters Distribution Agreement with Medigen Biotechnology Corp TBG Diagnostics Limited announces that its wholly owned subsidiary TBG Biotechnology Corp. entered into a distribution agreement with Medigen Biotechnology Corp. to distribute TBG Taiwan's SARS-CoV-2 related diagnostic products, including Rapid Test Kit (Colloidal Gold) and Nucleic Acid Test Kit . The Distribution Agreement has expanded Medigen's existing exclusive distribution right granted under the distribution contract previously entered into between TBG Taiwan and Medigen in January 2015 to include the Test Kits. This provides an ability for expansion of the business of manufacturing and distributing the Test Kits through the distribution expertise and network of Medigen. 
